Abstract
OBJECTIVE
To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms.
METHODS
Pooled data from four 12-week, randomized, double-blind, placebo-controlled studies of ropinirole in patients with moderate-to-severe primary RLS were analyzed post hoc. The relationship between age-at-onset and response to treatment, based on change from the baseline International Restless Legs Syndrome Study Group (IRLSSG) rating scale (the International Restless Legs Scale [IRLS]) total score and the proportion of responders (rated 'much'/'very much' improved) on the Clinical Global Impression-Improvement (CGI-I) scale, was explored.
RESULTS
The range of age-at-onset of RLS symptoms was 2-75 years. No relationship was observed between the age-at-onset of RLS symptoms and baseline IRLS total score (correlation r=-0.06), and between dose administered at Week 12 last observation carried forward (LOCF) and age-at-onset (r=-0.04). The age-at-onset by treatment interaction was non-significant (P=0.952 for the IRLS and P=0.716 for the CGI-I scale), indicating there was no significant relationship between age-at-onset and the magnitude of ropinirole treatment effect.
CONCLUSIONS
These data suggest that ropinirole provides effective relief of symptoms, regardless of age at RLS symptom onset.
TY - JOUR
T1 - Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset.
AU - Allen,Richard P,
AU - Ritchie,Sally Y,
Y1 - 2007/11/19/
PY - 2007/05/24/received
PY - 2007/08/20/revised
PY - 2007/08/22/accepted
PY - 2007/11/21/pubmed
PY - 2009/2/20/medline
PY - 2007/11/21/entrez
SP - 899
EP - 902
JF - Sleep medicine
JO - Sleep Med
VL - 9
IS - 8
N2 - OBJECTIVE: To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms. METHODS: Pooled data from four 12-week, randomized, double-blind, placebo-controlled studies of ropinirole in patients with moderate-to-severe primary RLS were analyzed post hoc. The relationship between age-at-onset and response to treatment, based on change from the baseline International Restless Legs Syndrome Study Group (IRLSSG) rating scale (the International Restless Legs Scale [IRLS]) total score and the proportion of responders (rated 'much'/'very much' improved) on the Clinical Global Impression-Improvement (CGI-I) scale, was explored. RESULTS: The range of age-at-onset of RLS symptoms was 2-75 years. No relationship was observed between the age-at-onset of RLS symptoms and baseline IRLS total score (correlation r=-0.06), and between dose administered at Week 12 last observation carried forward (LOCF) and age-at-onset (r=-0.04). The age-at-onset by treatment interaction was non-significant (P=0.952 for the IRLS and P=0.716 for the CGI-I scale), indicating there was no significant relationship between age-at-onset and the magnitude of ropinirole treatment effect. CONCLUSIONS: These data suggest that ropinirole provides effective relief of symptoms, regardless of age at RLS symptom onset.
SN - 1389-9457
UR - https://www.unboundmedicine.com/medline/citation/18024167/Clinical_efficacy_of_ropinirole_for_restless_legs_syndrome_is_not_affected_by_age_at_symptom_onset_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S1389-9457(07)00320-6
DB - PRIME
DP - Unbound Medicine
ER -
